<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>T2D Glycaemic Control: Clinical Quick-Scan</title>
    <style>
        :root {
            /* Clinical Color Palette */
            --col-red-alert: #dc2626;
            --col-red-bg: #fef2f2;
            --col-green-safe: #16a34a;
            --col-green-bg: #f0fdf4;
            --col-blue-info: #2563eb;
            --col-blue-bg: #eff6ff;
            --col-orange-warning: #ea580c;
            --col-orange-bg: #fff7ed;
            
            --text-main: #1e293b;
            --text-muted: #64748b;
            --bg-body: #f8fafc;
            --bg-card: #ffffff;
            
            --shadow-sm: 0 1px 2px 0 rgb(0 0 0 / 0.05);
            --shadow-md: 0 4px 6px -1px rgb(0 0 0 / 0.1);
            --radius: 8px;
        }

        * { box-sizing: border-box; }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, Helvetica, Arial, sans-serif;
            background-color: var(--bg-body);
            color: var(--text-main);
            line-height: 1.5;
            margin: 0;
            padding-bottom: 4rem;
        }

        /* Typography */
        h1, h2, h3, h4 { margin-top: 0; letter-spacing: -0.025em; }
        h1 { font-size: 1.75rem; font-weight: 700; color: var(--text-main); }
        h2 { font-size: 1.25rem; font-weight: 600; border-bottom: 2px solid #e2e8f0; padding-bottom: 0.5rem; margin-bottom: 1rem; }
        .text-sm { font-size: 0.875rem; }
        .text-xs { font-size: 0.75rem; }
        .font-bold { font-weight: 700; }
        .text-red { color: var(--col-red-alert); }
        .text-green { color: var(--col-green-safe); }
        .text-blue { color: var(--col-blue-info); }

        /* Layout Grid */
        .container {
            max-width: 1200px;
            margin: 0 auto;
            padding: 1rem;
            display: grid;
            grid-template-columns: 1fr;
            gap: 1.5rem;
        }

        @media (min-width: 1024px) {
            .container {
                grid-template-columns: 300px 1fr;
                align-items: start;
            }
            .full-width { grid-column: 1 / -1; }
            .sidebar-sticky { position: sticky; top: 1rem; }
        }

        /* Components: Cards */
        .card {
            background: var(--bg-card);
            border-radius: var(--radius);
            padding: 1.25rem;
            box-shadow: var(--shadow-sm);
            border: 1px solid #e2e8f0;
            transition: transform 0.2s, box-shadow 0.2s;
        }
        .card:hover {
            transform: translateY(-2px);
            box-shadow: var(--shadow-md);
        }

        /* Alert Banners */
        .alert-red { background: var(--col-red-bg); border-left: 4px solid var(--col-red-alert); }
        .alert-green { background: var(--col-green-bg); border-left: 4px solid var(--col-green-safe); }
        .alert-blue { background: var(--col-blue-bg); border-left: 4px solid var(--col-blue-info); }
        .alert-orange { background: var(--col-orange-bg); border-left: 4px solid var(--col-orange-warning); }

        /* Navigation */
        .nav-pills {
            display: flex;
            flex-wrap: wrap;
            gap: 0.5rem;
            list-style: none;
            padding: 0;
            margin-bottom: 1.5rem;
        }
        .nav-item {
            background: white;
            border: 1px solid #cbd5e1;
            border-radius: 20px;
            padding: 0.5rem 1rem;
            font-size: 0.875rem;
            cursor: pointer;
            transition: all 0.2s;
            font-weight: 500;
        }
        .nav-item:hover, .nav-item.active {
            background: var(--col-blue-info);
            color: white;
            border-color: var(--col-blue-info);
        }

        /* Data Tables */
        .data-table {
            width: 100%;
            border-collapse: collapse;
            font-size: 0.9rem;
        }
        .data-table th, .data-table td {
            padding: 0.75rem;
            text-align: left;
            border-bottom: 1px solid #e2e8f0;
        }
        .data-table th {
            background: #f1f5f9;
            font-weight: 600;
        }
        .data-table tr:hover {
            background-color: #f8fafc;
        }
        .cell-benefit { color: var(--col-green-safe); font-weight: bold; }
        .cell-harm { color: var(--col-red-alert); font-weight: bold; }
        .cell-neutral { color: var(--text-muted); }

        /* Mechanism Chips */
        .chip {
            display: inline-block;
            padding: 0.25rem 0.75rem;
            border-radius: 12px;
            font-size: 0.75rem;
            font-weight: 600;
            margin-right: 0.5rem;
            margin-bottom: 0.5rem;
        }
        .chip-met { background: #dbeafe; color: #1e40af; }
        .chip-gli { background: #fee2e2; color: #991b1b; }
        .chip-glp { background: #dcfce7; color: #166534; }
        .chip-sglt { background: #e0e7ff; color: #3730a3; }

        /* Tabs Logic */
        .tab-content { display: none; animation: fadeIn 0.3s ease-in-out; }
        .tab-content.active { display: block; }

        @keyframes fadeIn {
            from { opacity: 0; transform: translateY(5px); }
            to { opacity: 1; transform: translateY(0); }
        }

        /* Utility */
        .grid-2 { display: grid; grid-template-columns: 1fr; gap: 1rem; }
        @media (min-width: 768px) { .grid-2 { grid-template-columns: 1fr 1fr; } }

        .hidden { display: none; }
    </style>
</head>
<body>

<div class="container">
    <!-- Sidebar / Navigation -->
    <aside class="sidebar-sticky">
        <div class="card alert-blue">
            <h4 style="margin-top:0">Quick Navigator</h4>
            <p class="text-sm text-muted" style="margin-bottom:1rem">T2D Drugs & Glycaemic Control</p>
            <ul class="nav-pills" style="flex-direction: column; gap: 0.25rem;">
                <li class="nav-item active" onclick="showSection('overview')">üöë Red Flags & Rescue</li>
                <li class="nav-item" onclick="showSection('mechanisms')">üß† Cheat Sheet (MOA)</li>
                <li class="nav-item" onclick="showSection('guidance')">üìã NICE Guidance Path</li>
                <li class="nav-item" onclick="showSection('comparison')">üìä Drug Comparison</li>
                <li class="nav-item" onclick="showSection('safety')">‚ö†Ô∏è Safety & Dilemmas</li>
                <li class="nav-item" onclick="showSection('monitoring')">üìà Monitoring & Driving</li>
            </ul>
        </div>

        <div class="card" style="margin-top: 1rem;">
            <h4>Context</h4>
            <p class="text-xs text-muted">Updated: April 2025</p>
            <p class="text-sm"><strong>Key Change:</strong> Gliflozins (SGLT2i) now 1st line alongside Metformin for high CVD risk.</p>
        </div>
    </aside>

    <!-- Main Content Area -->
    <main>

        <!-- SECTION: RED FLAGS -->
        <section id="overview" class="tab-content active">
            <div class="card alert-red">
                <h3 style="color:var(--col-red-alert)">‚ö†Ô∏è Immediate Actions</h3>
                <ul class="text-sm" style="margin-bottom:0">
                    <li><strong>Symptomatic Hyperglycaemia:</strong> Consider 'Rescue Therapy' with Insulin or Sulphonylurea immediately.</li>
                    <li><strong>Severe Hypoglycaemia:</strong> Defined as impaired consciousness or requiring medical help. Doubles long-term CVD risk.</li>
                    <li><strong>DKA Risk:</strong> Gliflozins carry risk (2 more/1000 over 5y). Ensure Sick Day Rules are understood.</li>
                </ul>
            </div>

            <div class="grid-2" style="margin-top: 1.5rem;">
                <div class="card">
                    <h4>Targets (NICE 2022)</h4>
                    <table class="data-table">
                        <tr>
                            <td>Lifestyle / Non-hypo drug</td>
                            <td class="text-green font-bold">48 mmol/mol (6.5%)</td>
                        </tr>
                        <tr>
                            <td>Hypo-inducing drug (SU/Insulin)</td>
                            <td class="text-green font-bold">53 mmol/mol (7.0%)</td>
                        </tr>
                        <tr>
                            <td><strong>Intensify if HbA1c ></strong></td>
                            <td>58 mmol/mol (7.5%)</td>
                        </tr>
                    </table>
                    <p class="text-xs text-muted" style="margin-top:0.5rem">*De-intensify if HbA1c < 48. Always personalise.</p>
                </div>
                <div class="card">
                    <h4>Driving (DVLA Summary)</h4>
                    <p class="text-sm"><strong>Insulin / Sulphonylureas:</strong></p>
                    <ul class="text-xs">
                        <li>Must not have >1 severe hypo in last 12m (and none in last 3m).</li>
                        <li>Check glucose < 2hrs before driving & every 2 hrs.</li>
                    </ul>
                    <p class="text-sm"><strong>Non-hypo agents:</strong></p>
                    <ul class="text-xs">
                        <li>Group 1: Drive as normal.</li>
                        <li>Group 2: "Regular medical review".</li>
                    </ul>
                </div>
            </div>
        </section>

        <!-- SECTION: MECHANISMS -->
        <section id="mechanisms" class="tab-content">
            <h2>How Drugs Work (Cheat Sheet)</h2>
            <div class="grid-2">
                <div class="card">
                    <span class="chip chip-met">Metformin</span>
                    <p class="text-sm"><strong>Mnemonic:</strong> Sucks sugar out of blood into liver, muscle, fat. Good for heart.</p>
                </div>
                <div class="card">
                    <span class="chip chip-gli">Gliclazide (SU)</span>
                    <p class="text-sm"><strong>Mnemonic:</strong> Kicks pancreas to make more insulin. <span class="text-red">Watch out for Hypos.</span></p>
                </div>
                <div class="card">
                    <span class="chip chip-glp">GLP-1 Mimetics</span>
                    <p class="text-sm"><strong>Mnemonic:</strong> Mimic incretins (gut hormones). Augment insulin, slow stomach emptying (weight loss).</p>
                </div>
                <div class="card">
                    <span class="chip chip-sglt">Gliflozin (SGLT2i)</span>
                    <p class="text-sm"><strong>Mnemonic:</strong> Makes you pee out excess sugar. Great for Heart Failure & Renal protection.</p>
                </div>
            </div>
            
            <div class="card" style="margin-top:1rem">
                <h4>Specific Populations</h4>
                <div class="grid-2">
                    <div>
                        <p class="text-sm"><strong>COPD:</strong> GLP-1s reduce exacerbations (admissions). Gliflozins reduce admissions but not moderate exacerbations.</p>
                    </div>
                    <div>
                        <p class="text-sm"><strong>Renal:</strong> Gliflozins prevent ‚â•40% fall in eGFR. Check eGFR thresholds before starting.</p>
                    </div>
                </div>
            </div>
        </section>

        <!-- SECTION: GUIDANCE -->
        <section id="guidance" class="tab-content">
            <h2>Therapy Pathway (NICE/SIGN)</h2>
            
            <div class="card alert-blue">
                <h4>1st Line Strategy</h4>
                <div class="grid-2">
                    <div class="text-sm">
                        <strong>Standard:</strong> Metformin.<br>
                        <strong>High CVD Risk:</strong> Metformin <span class="font-bold">+</span> Gliflozin.<br>
                        <strong>Established CVD:</strong> Offer Gliflozin.
                    </div>
                    <div class="text-sm">
                        <em>Note: Gliflozins can be added at ANY stage if CVD/risk factors develop.</em>
                    </div>
                </div>
            </div>

            <div class="card">
                <h4>Second Line (After Metformin +/- Gliflozin)</h4>
                <p class="text-sm">Consider patient factors (frailty, weight, renal, hypo risk).</p>
                <ul class="text-sm" style="list-style-type: none; padding: 0;">
                    <li style="margin-bottom: 0.5rem; padding-bottom: 0.5rem; border-bottom: 1px solid #eee;">
                        <strong>Priority: Gliflozin (SGLT2i)</strong><br>
                        <span class="text-green">Best outcomes:</span> Lower HbA1c, lower BMI, lower BP, fewer HF admissions.
                    </li>
                    <li style="margin-bottom: 0.5rem; padding-bottom: 0.5rem; border-bottom: 1px solid #eee;">
                        <strong>Alternative: Gliptin (DPP-4i)</strong><br>
                        <span class="text-blue">Pros:</span> Weak but safe (no hypos).<br>
                        <span class="text-red">Cons:</span> Least effective if baseline HbA1c is high.
                    </li>
                    <li style="margin-bottom: 0.5rem; padding-bottom: 0.5rem; border-bottom: 1px solid #eee;">
                        <strong>Alternative: Sulphonylurea</strong><br>
                        <span class="text-red">Cons:</strong> High hypo risk, weight gain. Use with caution.
                    </li>
                    <li>
                        <strong>Specialist Use: GLP-1</strong><br>
                        <span class="text-green">Indication:</span> High BMI (BMI ‚â•35 with comorbidities, or ‚â•30).
                    </li>
                </ul>
            </div>
        </section>

        <!-- SECTION: COMPARISON -->
        <section id="comparison" class="tab-content">
            <h2>Drug Comparison (Meta-Analysis Data)</h2>
            <p class="text-sm text-muted">Events per 1000 patients over 5 years compared to standard care.</p>
            
            <div style="overflow-x: auto;">
                <table class="data-table">
                    <thead>
                        <tr>
                            <th style="min-width: 120px;">Drug Class</th>
                            <th>All-cause Mortality</th>
                            <th>CV Mortality</th>
                            <th>Heart Failure Admissions</th>
                            <th>End-Stage Renal Disease</th>
                            <th>Key Harms</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td class="font-bold">Gliflozin (SGLT2i)</td>
                            <td class="cell-benefit">17 fewer</td>
                            <td class="cell-benefit">14 fewer</td>
                            <td class="cell-benefit">33 fewer</td>
                            <td class="cell-benefit">34 fewer</td>
                            <td class="cell-harm text-xs">Genital infections, DKA, Amputations</td>
                        </tr>
                        <tr>
                            <td class="font-bold">GLP-1 Mimetic</td>
                            <td class="cell-benefit">17 fewer</td>
                            <td class="cell-benefit">13 fewer</td>
                            <td class="cell-benefit">9 fewer</td>
                            <td class="cell-benefit">14 fewer</td>
                            <td class="cell-harm text-xs">Severe GI events</td>
                        </tr>
                        <tr>
                            <td>Metformin</td>
                            <td class="cell-neutral">No impact</td>
                            <td class="cell-neutral">No impact</td>
                            <td class="cell-neutral">No impact</td>
                            <td class="cell-neutral">No impact</td>
                            <td class="text-xs text-muted">B12 deficiency risk</td>
                        </tr>
                        <tr>
                            <td>Sulphonylurea</td>
                            <td class="cell-neutral">No impact</td>
                            <td class="cell-neutral">No impact</td>
                            <td class="cell-neutral">No impact</td>
                            <td class="cell-neutral">No impact</td>
                            <td class="cell-harm text-xs">109 more Hypos/5y</td>
                        </tr>
                        <tr>
                            <td>Gliptin (DPP-4i)</td>
                            <td class="cell-neutral">No impact</td>
                            <td class="cell-neutral">No impact</td>
                            <td class="cell-neutral">No impact</td>
                            <td class="cell-neutral">No impact</td>
                            <td class="text-xs text-muted">Cholecystitis (rare)</td>
                        </tr>
                        <tr>
                            <td>Pioglitazone</td>
                            <td class="cell-neutral">No impact</td>
                            <td class="cell-neutral">No impact</td>
                            <td class="cell-harm">48 more</td>
                            <td class="cell-neutral">No impact</td>
                            <td class="text-xs text-muted">Weight gain, fractures</td>
                        </tr>
                        <tr>
                            <td>Basal Insulin</td>
                            <td class="cell-neutral">No impact</td>
                            <td class="cell-neutral">No impact</td>
                            <td class="cell-neutral">No impact</td>
                            <td class="cell-neutral">No impact</td>
                            <td class="cell-harm text-xs">39 more Hypos/5y</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="card alert-orange" style="margin-top: 1rem;">
                <h4>Head-to-Head (GRADE Trial)</h4>
                <p class="text-sm">
                    <strong>Winner (Glycaemic):</strong> Liraglutide (GLP-1) & Insulin Glargine.<br>
                    <strong>Winner (CV):</strong> Liraglutide showed superiority vs pooled average of others.<br>
                    <strong>Laggard:</strong> Sitagliptin (Gliptin) performed poorly in high baseline HbA1c.
                </p>
            </div>
        </section>

        <!-- SECTION: SAFETY -->
        <section id="safety" class="tab-content">
            <h2>Safety, Dilemmas & Special Topics</h2>
            
            <div class="grid-2">
                <div class="card">
                    <h4 class="text-blue">Metformin & B12</h4>
                    <ul class="text-sm">
                        <li>Risk of deficiency: <strong>1 in 10</strong>.</li>
                        <li><strong>Action:</strong> Check B12 if symptoms/signs present.</li>
                        <li><strong>Pragmatic Tip:</strong> Add B12 to annual diabetes bloods for those on Metformin.</li>
                    </ul>
                </div>
                <div class="card">
                    <h4 class="text-red">Sick Day Rules (Gliflozins)</h4>
                    <ul class="text-sm">
                        <li>Stop Gliflozins if acute illness/dehydration.</li>
                        <li>Risk of <strong>euglycaemic DKA</strong>.</li>
                        <li>Do not restart until eating/drinking normally for 24-48h.</li>
                    </ul>
                </div>
            </div>

            <div class="card" style="margin-top: 1rem;">
                <h4>Drug Dilemmas</h4>
                <details>
                    <summary class="text-sm font-bold" style="cursor:pointer; color:var(--col-blue-info)">Can we combine Gliptin + Sulphonylurea?</summary>
                    <div class="text-sm" style="margin-top: 0.5rem; padding-left: 1rem; border-left: 2px solid #e2e8f0;">
                        <span class="text-red font-bold">Caution:</span> Significant increase in hypoglycaemia (1 extra case per 17 people in first 6 months). BNF recommends reducing SU dose when starting gliptin.
                    </div>
                </details>
                <details>
                    <summary class="text-sm font-bold" style="cursor:pointer; color:var(--col-blue-info)">Can we combine Gliflozin + GLP-1?</summary>
                    <div class="text-sm" style="margin-top: 0.5rem; padding-left: 1rem; border-left: 2px solid #e2e8f0;">
                        <span class="text-green font-bold">Yes (beneficial):</span> Dual therapy shows summative benefits. Fewer CV events and renal events compared to monotherapy. (Note: NICE currently limits GLP-1s for obesity/cost, but evidence supports combo).
                    </div>
                </details>
                <details>
                    <summary class="text-sm font-bold" style="cursor:pointer; color:var(--col-blue-info)">GLP-1s and Suicidality?</summary>
                    <div class="text-sm" style="margin-top: 0.5rem; padding-left: 1rem; border-left: 2px solid #e2e8f0;">
                        <span class="text-green font-bold">Reassuring:</span> Large cohort studies found NO increased risk of suicide vs other diabetes drugs. Some even showed protective effects.
                    </div>
                </details>
                <details>
                    <summary class="text-sm font-bold" style="cursor:pointer; color:var(--col-blue-info)">Gastric Emptying (Rapid vs Delayed)</summary>
                    <div class="text-sm" style="margin-top: 0.5rem; padding-left: 1rem; border-left: 2px solid #e2e8f0;">
                        <strong>Emerging Concept:</strong> 20% of poorly controlled diabetics have <em>rapid</em> gastric emptying (not just delayed). Rapid emptying worsens post-prandial hyperglycaemia. Treating delayed emptying might worsen sugar control.
                    </div>
                </details>
            </div>
        </section>

        <!-- SECTION: MONITORING -->
        <section id="monitoring" class="tab-content">
            <h2>Monitoring Guidelines</h2>

            <div class="card">
                <h4>Who needs Blood Sugar Monitoring?</h4>
                <table class="data-table">
                    <thead>
                        <tr>
                            <th>Monitoring Type</th>
                            <th>Offer To...</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Capillary (Finger prick)</strong></td>
                            <td class="text-sm">
                                - On Insulin<br>
                                - History of hypoglycaemia<br>
                                - On Steroids<br>
                                - DVLA requirements
                            </td>
                        </tr>
                        <tr>
                            <td><strong>Continuous (Flash/rtCGM)</strong></td>
                            <td class="text-sm">
                                - On Multiple Daily Injections (MDI) + recurrent/severe hypos<br>
                                - Impaired hypo awareness<br>
                                - Disability preventing finger pricks
                            </td>
                        </tr>
                    </tbody>
                </table>
                <p class="text-xs text-muted" style="margin-top:1rem">*For all others, routine self-monitoring is NOT indicated (high quality RCTs show no HbA1c difference).</p>
            </div>

            <div class="card" style="margin-top: 1rem;">
                <h4>Driving Rules Snapshot</h4>
                <div class="grid-2">
                    <div class="alert-red" style="padding:0.5rem; border-radius:4px;">
                        <strong>Group 1 (Car)</strong><br>
                        <span class="text-xs">If on Insulin/SU:</span> No >1 severe hypo in 12m. Test <2h before drive.
                    </div>
                    <div class="alert-red" style="padding:0.5rem; border-radius:4px;">
                        <strong>Group 2 (HGV/LGV)</strong><br>
                        <span class="text-xs">If on Insulin:</span> NO severe hypos in 12m. Finger prick ONLY (no flash allowed for testing).
                    </div>
                </div>
            </div>
        </section>

    </main>
</div>

<script>
    function showSection(sectionId) {
        // Update Tab Content
        document.querySelectorAll('.tab-content').forEach(el => {
            el.classList.remove('active');
        });
        document.getElementById(sectionId).classList.add('active');

        // Update Nav Pills
        document.querySelectorAll('.nav-item').forEach(el => {
            el.classList.remove('active');
        });
        
        // Find the clicked nav item based on onclick attribute matching
        const navItems = document.querySelectorAll('.nav-item');
        navItems.forEach(item => {
            if(item.getAttribute('onclick').includes(sectionId)) {
                item.classList.add('active');
            }
        });

        // Scroll to top of main on mobile for better UX
        if(window.innerWidth < 1024) {
            window.scrollTo({ top: 0, behavior: 'smooth' });
        }
    }
</script>

</body>
</html>